Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rabeprazole-based triple vs bismuth-based quadruple therapy for Helicobacter pylori eradication in children
ChiCTR2300070994Phase 4Not yet recruiting
- Sponsor
- Guangzhou Women and Children's Medical Center
- Start
- May 2023
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of rabeprazole, amoxicillin, clarithromycin and bismuth subcitrate in Helicobacter pylori infection (2 arms), sponsored by Guangzhou Women and Children's Medical Center. Primary endpoint: Eradication rate of Helicobacter pylori. Planned start May 2023; status: not yet recruiting.
02
Drugs
rabeprazoleamoxicillinclarithromycinbismuth subcitrate
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on ChiCTR2300070994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300070994.